Recent research in cell death mechanisms has rekindled interest in PARP's (Poly (ADP-Ribose) Polymerase) intriguing role in necrosis and apoptosis. While the details of how PARP1 functions are still being elucidated, it has tremendous potential as a promising drug target. PARP inhibitors' dual actions of preventing cell death and abating inflammation have demonstrated remarkable acute effects in animal models of various diseases.

PARP as a Therapeutic Target covers the clinical aspects of this up-and-coming drug that counteracts the damage done by free radicals. Leading international experts currently working on ways to apply it share their views of recent developments and future directions of PARP research. They discuss its therapeutic potential in various disease conditions, such as ischemia, diabetes, cancer, arthritis, inflammatory bowel disease, and septic shock.

The intensified PARP drug development effort has raised expectations for possible clinical trials in the near future to establish the tolerance of PARP inhibitors in healthy humans, its efficacy in treating patients with different diseases, and the long term effect of PARP inhibition. PARP as a Therapeutic Target provides a comprehensive understanding of how PARP works to aid in the better design of its inhibitors for therapeutic purposes.